89Bio Inc

89Bio Inc (ETNB)

-0.53 (-2.08%)
Symbol ETNB
Price 25$
Beta 0.000
Volume Avrg. 0.16M
Market Cap 0.42B
Shares (2019) 13,788.98K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -63.84% Strong Sell
ROA -60.09% Strong Sell
Operating Margin -Infinity% Strong Sell
Debt / Equity 6.24% Neutral
P/E -1.24 Sell
P/B 0.79 Buy

Retained Earning Schedule

Year 2018 2019
Retained Earnings (Previous Year) --16
Net Income -16-57
Stock Dividends --
Dividend Paid --
Retained Earnings -16-74

PPE Schedule

Year 2018 2019
Gross PPE -0
Annual Depreciation 00
Capital Expenditure -0-0
Net PPE 00

Intangible and Goodwill Schedule

Year 2018 2019
Intangible and Goodwill (Previous Year) --
New Purchases --
Intangible and Goodwill --


Mr. Rohan Palekar

89bio, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 17 full-time employees. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism.